Skip to main content
SpringerLink
Log in

Febuxostat vs allopurinol: real-world cardiovascular safety

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Su C-Y, et al. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study. Mayo Clinic Proceedings 94: 1147-1157, No. 7, Jul 2019. Available from: URL: http://doi.org/10.1016/j.mayocp.2019.03.001

  2. Mankad R. Cardiovascular Safety of Febuxostat Versus Allopurinol in the Real World: Old Reliable Comes Out on Top. Mayo Clinic Proceedings 94: 1128-1130, No. 7, Jul 2019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Febuxostat vs allopurinol: real-world cardiovascular safety. Reactions Weekly 1762, 6 (2019). https://doi.org/10.1007/s40278-019-64745-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-64745-z

Search

Navigation